Physician profile
Michael J Miller
NPI 1194719559
$10,439.55
in general payments reported to CMS, 2019-2025
40 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $1,410 · 2021: $1,180 · 2022: $1,264 · 2023: $2,228 · 2024: $1,767 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,228.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,382.06 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,058.73 | 2019-2025 | |
| Pfizer INC. | $855.64 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $777.64 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Janssen Pharmaceuticals, INC | $775.88 | 2019-2024 | Xarelto |
| Amgen INC. | $722.89 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $669.14 | 2021-2025 | Verquvo |
| Abbott Laboratories | $440.46 | 2021-2025 | Coroflow, Cardiomems, Xience Skypoint |
| Shockwave Medical, INC | $412.08 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $358.12 | 2019-2025 | Eliquis, Camzyos |
| Abiomed | $342.97 | 2019-2024 | Impella |
| Boston Scientific Corporation | $316.82 | 2019-2025 | Watchman Flx, Eluvia, Rubicon 18 |
| Medtronic, INC. | $289.12 | 2023-2025 | Azure Xt Dr Mri Surescan, Selectsecure |
| Preventric Diagnostics, INC. | $278.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $193.79 | 2019 |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.